Lv21
144 积分 2022-08-08 加入
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
3天前
已完结
HR+/HER-2－早期乳腺癌复发⻛险与临床管理专家共识（2025版）
6天前
已完结
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
10天前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
10天前
已完结
德曲妥珠单抗在乳腺癌治疗的研究进展
17天前
已完结
Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1
18天前
已关闭
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
27天前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
1个月前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
1个月前
已关闭
VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial
1个月前
已完结
皖公网安备34019202002308
